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“Nothing in life is to be feared, it is only to be understood. Now is the time to 
understand more, so that we may fear less.”   
 
Marie Curie 
 
 
  
ABSTRACT 
 
Pulmonary hypertension (PH) is a progressive obliterative vasculopathy with multifactorial etiology 
and high mortality rate. Endothelial dysfunction, excessive vascular remodeling, inflammation and in 
situ thrombosis contribute to increased vascular resistance and gradual occlusion of pulmonary 
vessels. Sustained high pressure in the pulmonary circulation increases right heart afterload and 
ultimately results in right heart failure. Current pharmacological treatments, like endothelin receptor 
antagonists, prostacyclin analogues, and phosphodiesterase-5 inhibitors, are primarily vasodilators and 
exert limited effects on vascular remodeling. Survival has improved, but far from enough, and the 
demand for lung transplantation has not been reduced.  
Excessive growth of pulmonary artery smooth muscle cells (PASMCs) contributes to intimal 
hyperplasia, medial wall thickening, and plexiform lesions, the main features of vascular remodeling 
in PH. It is therefore important to explore factors which can control PASMC growth in order to 
identify potential targets for regression of PH. 
Here, the roles of growth factors and proteoglycans in vascular remodeling were investigated in 
animal models of PH as well as in tissue specimens from patients.  
In a rat model of PH associated with congenital diaphragmatic hernia, up-regulation of PDGF-B was 
found. Prenatal PDGF-B inhibition by imatinib, a tyrosine kinase inhibitor, was demonstrated to 
inhibit PASMC proliferation and to reduce pulmonary vascular remodeling in fetal rat lungs.  
In a murine model of hypoxia-induced PH, increased perlecan deposition was observed. Genetically 
modified mice expressing heparan sulfate-deficient perlecan developed less PH, accompanied by 
decreased pulmonary vascular remodeling and reduced right ventricular hypertrophy. In addition, 
defective mural cell recruitment in pulmonary vessels was observed in heparan sulfate-deficient mice. 
A possible mechanism is impaired interaction between FGF-2 and its receptor and a pro-proliferative 
function for perlecan heparan sulfate in pulmonary vessels. The role of PDGF-B retention motifs, the 
C-terminal region of PDGF-B that interacts with heparan sulfate, was also explored. Hypoxia-induced 
PH was reduced in PDGF-B retention motif knockout, possibly due to defective retention of PDGF-B 
in the extracellular matrix and disturbed recruitment of mural cells. 
Metabolic labeling experiments showed that a majority of the proteoglycans secreted by human 
PASMCs are decorated with chondroitin sulfate. Lung tissue sections from patients with PH revealed 
versican accumulation in vascular lesions. In vitro, mechanical strain and hypoxia increased versican 
production in PASMCs. The results suggested that versican is a pro-proliferative element in the 
vascular remodeling of PH.  
In summary, this thesis work emphasizes the role of growth factors and proteoglycans, and 
interactions between the two, in the regulation of PASMC growth during PH development. Inhibition 
of growth factor activity or specific targeting of important functional domains of proteoglycans may 
be effective anti-remodeling strategies for future PH treatment. 
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INTRODUCTION 
 
CLINICAL BACKGROUND 
Pulmonary hypertension (PH) is a progressive occlusive vasculopathy in the lung, associated 
with abnormal vasoconstriction, excessive vascular wall remodeling, inflammation and in situ 
thrombosis. Increased vascular resistance accounts for a sustained elevation of blood pressure 
in the pulmonary circulation, leading to increased afterload for the right ventricle and 
eventually to right heart failure. 
The clinical manifestations of pulmonary hypertension are non-specific. The patients may 
have cardiopulmonary symptoms, e.g. dyspnea, chest discomfort, decreased appetite, fatigue, 
dizziness, and irregular heartbeat. The diagnosis of pulmonary hypertension requires a 
thorough physical examination and extensive tests including Doppler echocardiography and 
pulmonary function tests. The diagnosis should in most cases be confirmed by right heart 
catheterization, which when positive shows a mean pulmonary arterial pressure ≥ 25 mmHg 
at rest. Based on the clinical features and underlying etiologies, pulmonary hypertension is 
classified into 5 categories by the World Health Organization (WHO). Group I is pulmonary 
arterial hypertension (PAH), in which the pulmonary vascular pathology is pre-capillary. 
Group II indicates PH as a result of left heart disease. Group III PH is associated with lung 
diseases. Group IV PH is secondary to chronic   thromboembolism and PH with unclear 
multifactorial mechanisms belongs to Group V. The following table (Table 1) shows the 
updated clinical classification as summarized at the 5th World Symposium on Pulmonary 
Hypertension in 2013 (Simonneau et al., 2013).  
Currently established pharmacotherapy consists of prostacyclin analogues (e.g. epoprostenol, 
iloprost, and treprostinil), endothelin receptor antagonists (e.g. bosentan and ambrisentan), 
and phosphodiesterase-5 (PDE-5) inhibitors (e.g. sildenafil and tadalafil). Prostanoids exert 
many effects in the pulmonary vessels including vasodilatation, inhibition of proliferation and 
inflammation, and suppression of platelet aggregation (Clapp and Gurung, 2015). Endothelin 
receptor antagonists not only act as vasodilators, but also inhibit proliferation of smooth 
muscle cells and fibroblasts (reviewed in Humbert et al., 2014). The PDE-5 inhibitors are 
potent vasodilators which reduce vascular tone through the nitric oxide pathway.   
In general, pulmonary hypertension is a rare but severe cardiopulmonary disorder (George et 
al., 2014). The above mentioned treatments mainly address endothelial dysfunction and the 
vasodilatory effects are the most prominent. Pulmonary hemodynamic parameters are often 
improved with current therapy and survival has improved to some extent, but far from 
enough. PH remains incurable, and the long-term prognosis is still poor (Ling et al., 2012, 
Benza et al., 2012, George et al., 2014). More investigations are needed to explore new 
therapeutic targets to improve quality of life as well as long-term outcome.  
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Reprinted with permission (Simonneau et al., 2013). 
 
 
PATHOBIOLOGY 
The histopathological findings in PH consists of intimal hyperplasia, medial hypertrophy 
(thickening), distal extension of smooth muscle cells into normally non-muscular intra-acinar 
vessels, adventitial proliferation and fibrosis, occlusion of small arteries/plexiform lesions, 
thrombosis in situ, and infiltration of inflammatory cells and progenitor cells (Figure 1). All 
cell types of the pulmonary vessel wall participate in the process of vascular remodeling 
(Tuder et al., 2007, Tuder et al., 2013, Yeager et al., 2011, Jonigk et al., 2011).  
Table 1. Classification of Pulmonary Hypertension
1. Pulmonary arterial hypertension
1.1 Idiopathic PAH
1.2 Heritable PAH: (i)BMPR2, (i i)ALK-1, ENG, SMAD9, CAV1, KCNK3, (i i i)unknown
1.3 Drug and toxin induced
1.4 Associated with:
1.4.1 Connective tissue disease
1.4.2 HIV infection
1.4.3 Portal hypertension
1.4.4 Congenital heart diseases
1.4.5 Schistosomiasis
1' Pulmonary veno-occlusive disease and/or pulmonary capil lary hemangiomatosis
1'' Persistent pulmonary hypertension of the newborn (PPHN)
2. Pulmonary hypertension due to left heart disease
2.1 Left ventricular systolic dysfunction
2.2 Left ventricular diastolic dysfunction
2.3 Valvular disease
2.4 Congenital/acquired left heart inflow/outflow tract obstruction and congenital cardiomyopathies
3. Pulmonary hypertension due to lung diseases and/or hypoxia
3.1 Chronic obstructive pulmonary disease
3.2 Interstitial lung disease
3.3 Other pulmonary diseases with mixed restrictive and obstructive pattern
3.4 Sleep-disordered breathing
3.5 Alveolar hypoventilation disorders
3.6 Chronic exposure to high altitude
3.7 Development lung diseases
4. Chronic thromboembolic pulmonary hypertension
5. Pulmonary hypertension with unclear multifactorial mechanisms
5.1 Hematologic disorders: chronic hemolytic anemia, myeloproliferative disorders, splenectomy
5.2 Systemic disorders: sarcoidosis, pulmonary histiocytosis, lymphangioleiomyomatosis
5.3 Metabolic disorders: glycogen storage disease, Gaucher disease, thyroid disorders
5.4 Others: tumoral obstruction, fibrosing mediastinitis, chronic renal failure, segmental PH
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Figure 1. Schematic illustration of vascular remodeling in PH. The pathological findings 
include abnormal muscularization of distal precapillary arterioles, medial wall thickening of 
large muscular arteries, neointima formation, loss of precapillary arterioles, and plexiform 
lesion formation. Reprinted with permission (Rabinovitch, 2012). 
 
Pulmonary artery 
The pulmonary circulation is a high-flow, low-pressure, low-resistance system that carries 
deoxygenated blood from the right ventricle to the lungs for gas exchange.  Normally, the 
main pulmonary artery pressure is around 20 mmHg, with systolic pressure 15-30 mHg and 
diastolic pressure 4-12 mmHg, as measured by right heart catheterization (Taichman et al., 
2015).  
In the development of the cardiovascular system the main pulmonary artery originates from 
the 6th pharyngeal arch at 3rd-5th week of human embryonic life.  Following branching into 
right and left pulmonary arteries, the vessels merge with the lung buds. The proximal 
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pulmonary vascular branching then develops in parallel with airway branching. The distal 
pulmonary arteries originate from de novo vasculogenesis and angiogenesis within the lung 
parenchyma at a later developmental stage (16th -26th  week) (Jones and Capen, 2011). 
The proximal pulmonary arteries (conduit arteries) contain several layers of elastic laminae. 
The transitional and segmental pulmonary arteries are typically muscular arteries where 
smooth muscle cells (SMCs) lie between the internal elastic lamina and the external elastic 
lamina. The distal pulmonary arterioles are usually partially muscular or non-muscular.  
 
Endothelial cells 
Endothelial cells (ECs) form the innermost layer of the vascular wall and play important roles 
in maintenance of selective permeability, control of vascular tone, recruitment of 
inflammatory cells and regulation of thrombosis and hemostasis. Endothelial dysfunction 
contributes to reduced bioavailability of nitric oxide and impaired EC-dependent 
vasodilatation, as well as endothelial inflammatory activation and pro-thrombotic activity 
(Figure 2).  
 
 
 
Figure 2. Endothelial dysfunction includes impairment of EC-dependent vasodilatation, 
increased permeability, and activation of inflammation and thrombosis.  
 
In physiological conditions, ECs synthesize and release nitric oxide and prostacyclin (also 
called prostaglandin I2 or PGI2), both potent vasodilators and inhibitors of platelet 
aggregation. In response to environmental changes, like hypoxia or increased pressure/wall 
stress, ECs produce endothelins (mainly endothelin-1) to stimulate smooth muscle 
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contraction (Hunt et al., 2002). Endothelin-1 also recruits leukocytes (Teder and Noble, 2000, 
Bhavsar et al., 2008) and transactivates growth factor receptor signaling associated with 
smooth muscle cell proliferation (reviewed in Sandoval et al., 2014). In PH, the balance 
between endogenous vasodilators (e.g. decreased nitric oxide and prostacyclin) and 
vasoconstrictors (e.g. increased endothelin-1) is disrupted, resulting in excessive 
vasoconstriction and vascular remodeling (reviewed in Budhiraja et al., 2004).  
 
Smooth muscle cells 
SMCs are found in the medial layer of the vessel wall. Studies of SMCs in vitro, as well as in 
arterial tissues, support the hypothesis that the vascular SMC population is not uniform. 
Instead, SMCs are functionally and phenotypically heterogeneous in both systemic arteries 
and pulmonary arteries (Frid et al., 1994, Benzakour et al., 1996, Frid et al., 1997). In normal 
adult blood vessels, SMCs are in a differentiated state and have a contractile phenotype. In 
response to injury, SMCs phenotypically switch to a synthetic state, in which their ability to 
migrate, proliferate, and produce extracellular matrix is increased (Hedin et al., 2004). SMCs 
regulate vascular tone by vasoconstriction or relaxation. Pulmonary artery smooth muscle cell 
(PASMC) hypertrophy, proliferation, migration, and resistance to apoptosis contribute to 
vascular remodeling and play an important role in PH (Figure 3). 
 
 
Figure 3. The schematic diagram shows the role of SMC in vascular remodeling.   
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K+ channels 
K+ channels are the most widely distributed ion channels on cell membranes. There are four 
classes of K+ channels; voltage-gated K+ channels, Ca2+-activated K+ channels, tandem pore 
domain K+ channels, and inward rectifier K+ channels. Certain voltage-gated K+ channels, 
e.g. KV1.2, KV 1.5, KV 2.1, KV 3.1, are oxygen-sensitive and regulated by reactive oxygen 
species (ROS) (reviewed in Moudgil et al., 2006). In PASMC, acute hypoxia inhibits KV1.5, 
which in turn depolarizes the cell membrane followed by opening of voltage-gated Ca2+ 
channels (Archer et al., 1998). The resulting increase in intracellular Ca2+ concentration 
initiates hypoxic pulmonary vasoconstriction. Notably, the KV1.5 protein is more abundant in 
distal resistance pulmonary arteries compared to proximal conduit pulmonary arteries (Archer 
et al., 2004). This may in part explain why hypoxic pulmonary vasoconstriction 
predominantly occurs in distal intra-acinar pulmonary arteries.  
 
Free cytosolic Ca2+ 
Intracellular calcium ion concentration is regulated by calcium influx through calcium ion 
channels and intracellular release from the sarcoplasmic reticulum.  The free cytosolic Ca2+ 
level is the key determinant of SMC contraction. In addition, increased intracellular free 
calcium is essential for growth factor-induced SMC proliferation (Mogami and Kojima, 
1993, Magnier-Gaubil et al., 1996).  
 
Serotonin 
Serotonin, or 5-hydroxytryptophan (5-HT), is a monoamine neurotransmitter derived from 
the amino acid tryptophan. Serotonin can be found in the gastrointestinal tract, the central 
nervous system, platelets, and also in ECs. Several studies have demonstrated that serotonin 
mediates vasoconstriction and PASMC proliferation (Kahn et al., 1992, Pitt et al., 1994, Lee 
et al., 1994). Overproduction of serotonin in pulmonary ECs derived from patients with PH 
has also been shown to increase PASMC growth (Eddahibi et al., 2006). Furthermore, the 
serotonin transporter responsible for internalization of serotonin is of importance for PASMC 
proliferation in PH lungs (Marcos et al., 2004).  
 
Growth factors 
Transforming growth factor (TGF) and bone morphogenetic protein receptor (BMPR) 
The TGF-β superfamily is comprised of a large family of cytokine growth factors including 
TGF-β proteins, bone morphogenetic proteins, activins, and other regulatory proteins. TGF-β 
not only controls cell cycle progression, cell differentiation and ECM protein secretion, but 
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also has a crucial role in cell re-programming and epithelial-mesenchymal transition (Xie et 
al., 2013, reviewed in Massague, 2012).  
BMPR2 is one of the receptors for growth factors in the TGF-β superfamily. BMPR2 loss of 
function mutations have been shown to be associated with hereditary PAH and some sporadic 
idiopathic PAH (International et al., 2000, Deng et al., 2000). Several studies have revealed 
that BMPR2 signaling promotes EC survival while SMC proliferation is inhibited (de Jesus 
Perez et al., 2009, Hansmann et al., 2008).  However, most family members who carry 
BMPR2 mutations do no develop familial PAH (Hamid et al., 2009), suggesting that other 
factors affect disease penetrance. 
 
Platelet-derived growth factors (PDGFs) 
PDGF was first identified as a platelet-dependent serum factor for SMC and fibroblast 
proliferation (Kohler and Lipton, 1974, Ross et al., 1974).  So far the PDGF family comprises 
four polypeptides (PDGF-A, PDGF-B, PDGF-C and PDGF-D) that can form dimeric 
isoforms. In vivo, PDGFs form active disulfide-linked homodimers that bind PDGF receptor-
α or PDGF receptor-β (PDGFR-β) (Figure 4). One heterodimer, PDGF-AB, has been found 
in human platelets (Hammacher et al., 1988). However, the role of PDGF-AB remains 
unclear. 
 
 
Figure 4. The illustration shows the PDGF-PDGFR interaction in vivo. Gray rectangles 
indicate retention motifs comprising basic amino acids residues (adapted from Andrae et al., 
2008). 
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PDGFs act as mitogens and chemoattractants for cells of mesenchymal origin. In particular, 
PDGF-B is a strong mitogen for SMCs. Often more potent than fibroblast growth factor-2. 
PDGF-B is especially important in the vasculature and plays a critical role in cell 
proliferation, migration, differentiation and angiogenesis (see reviews, Hughes et al., 1996, 
Heldin and Westermark, 1999, Hoch and Soriano, 2003, Andrae et al., 2008).  
In the angiogenic process, PDGF-B/ PDGFR-β interaction is crucial for recruitment of mural 
cells, pericytes and SMCs, to cover nascent endothelial sprouts (Lindahl et al., 1997, Enge et 
al., 2002). PDGF-B released from vascular ECs promote proliferation of PDGFR-β 
expressing pericytes and SMCs. PDGF-B also acts as chemoattractant to direct the migration 
of pericytes and SMCs along newly formed endothelial sprouts (Hellstrom et al., 1999).  
It has been shown that the carboxy-terminus of PDGF-B has a high proportion of basic amino 
acid residues, which is important for cell membrane retention properties (Ostman et al., 1991, 
LaRochelle et al., 1991). Extracellular proteolytic cleavage of those “retention motifs” is 
thought to determine the release of PDGF-B from cell association or storage in the 
extracellular matrix. The mitogenic activity is retained after cleavage. The binding of PDGF 
retention motifs to negatively charged proteoglycans may be important for chemotactic 
gradients guiding recruitment of mural cells. Defective pericyte attachment in microvessels of 
PDGF-B retention motif knockout mice (Pdgfb ret/ret) supports this hypothesis (Lindblom et 
al., 2003).    
Aberrant PDGF regulation and signaling has been demonstrated in many studies of PH. 
Upregulation of PDGF transcripts was reported in a rodent model of hypoxic PH (Katayose et 
al., 1993) and increased PDGF receptor expression was observed in a lamb model with 
perinatal PH induced by ligation of the ductus arteriosus (Balasubramaniam et al., 2003). 
PDGF inhibition by imatinib, a tyrosine kinase inhibitor, successfully reverses PH in both 
chronic hypoxic mice and monocrotaline-treated rats (Schermuly et al., 2005). In patients 
with idiopathic PAH, overproduction of PDGF and PDGFR-β has been found in small 
pulmonary arteries, mainly localized to PASMC and ECs with perivascular inflammation 
(Perros et al., 2008). Imatinib treatment of patients with PAH reached phase III clinical trials 
and was shown to improve hemodynamics and right heart function in patients with severe 
PAH. However, imatinib has not been approved for use in PH due to severe side effects such 
as subdural hematomas (Hoeper et al., 2013, Shah et al., 2015). 
 
Fibroblast growth factors (FGFs) 
Many decades ago, FGFs were identified as mitogens and angiogenic factors. Currently, the 
FGF family consists of 18 members (FGF1-FGF10, and FGF16-FGF23). FGF11-FGF14 do 
not activate FGF receptors and are therefore not considered as part of the FGF family 
(Beenken and Mohammadi, 2009). By activating the FGF receptor tyrosine kinases (FGFR1-
FGFR4), FGFs are known to have a vast range of biological functions both in development 
and diseases.  
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FGF-2, or basic fibroblast growth factor, has been widely used as a mitogen and 
chemoattractant for ECs and SMCs in vitro. However, the physiological function of FGF-2 
has not been fully elucidated. FGF-2 can be translated into different isoforms from a single 
mRNA. In rodents, 3 isoforms with molecular weight of 18 kDa, 22 kDa, and 25 kDa have 
been identified (Shing et al., 1984, Presta et al., 1988, Moscatelli et al., 1987), while 5 
isoforms have been identified in humans (Abraham et al., 1986, Florkiewicz and Sommer, 
1989, Arnaud et al., 1999).  
The 18 kDa FGF-2, or low molecular weight (LMW)-FGF-2 is translated from a 
conventional AUG start codon, whereas others (high molecular weight (HMW)-FGF-2) are 
initiated by alternative upstream CUG codons (Prats et al., 1989) (Figure 5). LMW-FGF-2 is 
released into the extracellular space, but can also be found in the nucleoli. HMW-FGF-2 
predominantly localizes in the nucleus. However, a recent report showed that HMW-FGF-2 
can be released extracellularly (Santiago et al., 2011).  
 
Figure 5. FGF-2 isoforms 
 
In vascular biology, compelling evidence has revealed that LMW-FGF-2 is essential for 
endothelial sprouting in angiogenesis (reviewed in Lieu et al., 2011). On the other hand, 
HMW-FGF-2 contributes to cardiac hypertrophy both in vitro and in vivo (Jiang et al., 2007, 
Santiago et al., 2010).  
Notably, overproduction of FGF-2 has been shown in patients with PH (Benisty et al., 2004) 
as well as in an animal model (Wedgwood et al., 2007). Furthermore, it has been 
demonstrated that endothelial-derived FGF-2 contributes to SMC proliferation in humans and 
rats, and the use of either FGF-2 siRNA or an FGFR inhibitor inhibits vascular remodeling 
and nearly reverses PH development in monocrotaline-treated rats (Izikki et al., 2009). 
Collectively, the data suggest that FGF-2 may become a therapeutic target for treatment of 
PH.  
In addition to TGF-β, PDGF-B, and FGF-2, other growth factors like vascular endothelial 
growth factor (VEGF) and epidermal growth factor (EGF), take part in the vascular 
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remodeling in PH (Partovian et al., 1998, Geiger et al., 2000, Farkas et al., 2009, Dahal et al., 
2010), but their roles will not be described in detail in this thesis.  
 
Transcription factors  
Hypoxia-inducible factors (HIFs) 
HIFs are transcription factors that function as key sensors for cellular oxygenation. Through 
binding to the hypoxia-responsive elements in the promotor region of hundreds of genes and 
activation of gene transcription, multiple biochemical events are triggered and cells are able 
to adapt to the low oxygen level for survival (reviewed in Greer et al., 2012).  
HIF-1 is composed of an oxygen-sensitive α subunit and a constitutively expressed β subunit. 
In normoxia, the α subunit is rapidly degraded while under hypoxia the degradation is 
inhibited, which stabilizes the dimerization of HIF-1α with HIF-1β (Wang et al., 1995, Wang 
and Semenza, 1995). HIF-1α is an essential element for the physiological response to chronic 
hypoxia and has been shown to contribute to hypoxia-induced PH (Yu et al., 1999, Wang et 
al., 2006). HIF-1α can induce endothelin-1 expression in ECs (Hu et al., 1998) and 
endothelin-1 will also increase HIF-1α synthesis in SMCs (Pisarcik et al., 2013). A recent 
study showed reduced hypoxia-induced pulmonary vascular remodeling in SMC-specific 
HIF-1α inducible knockout mice (Ball et al., 2014), which further supports a central role of 
HIF-1α in the development of PH. 
Peroxisome proliferator-activated receptor γ (PPAR γ) 
PPAR γ is a ligand-activated transcription factor belonging to the nuclear hormone receptor 
superfamily. PPAR γ has a DNA-binding domain and a ligand-binding domain and it is 
expressed in ECs, SMCs, cardiomyocytes, and macrophages.  In normal conditions, PPAR γ 
is widely expressed in various cell types in the lung. In patients with PAH, PPAR γ is 
decreased in plexiform lesions, contributing to apoptosis-resistance properties of ECs 
(Ameshima et al., 2003). Reduction of PPAR γ expression has been found in animal models 
of PH, and PPAR γ activation by use of PPAR γ ligands such as pioglitazone or troglitazone 
have been shown to reduce PH in animal models. Recent investigations suggest that PPAR γ 
takes part in many pathways implicated in PH pathobiology (reviewed in Green et al., 2011). 
PPAR γ activation can reduce vasoconstriction and vascular remodeling. In addition, it has 
anti-inflammatory and anti-thrombotic effects. However, since the clinical use of PPAR γ 
ligands for other purposes has revealed increased risk of myocardial infarction and heart 
failure (Nissen and Wolski, 2007, Lincoff et al., 2007) clinical use in PH is not considered 
currently.   
Wnt/β-catenin 
The canonical Wnt/ β-catenin pathway regulates cell proliferation and differentiation and 
plays important roles in embryonic development and tissue homeostasis. It has been shown 
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that Wnt7b, expressed in lung epithelium, regulates mesenchymal differentiation essential for 
PASMC development in the mouse lung. Wnt7b/ β-catenin promote proliferation of PASMC 
precursors via activation of tenascin C, which is essential for PDGF receptor expression 
(Cohen et al., 2009). 
 
Nuclear factor of activated T cells (NFAT) 
NFAT is a Ca2+/calcineurin-sensitive transcription factor. It has been demonstrated that 
activated NAFTc2 in PASMC from patients with IPAH contributes to decreased K+ channel 
KV1.5 expression, increased intracellular free Ca2+ and K+ concentrations and PASMC 
contraction as well as proliferation (Bonnet et al., 2007).  
Pericytes 
Pericytes, also known as Rouget cells, are mural cells which have “peg-socket contacts” with 
the endothelium in microvessels (reviewed in Armulik et al., 2005). Pericytes are present in 
precapillary arterioles, capillaries, and postcapillary venules and share the basement 
membrane with ECs. Even though the identity of pericytes is difficult to define, this cell type 
can be distinguished from SMCs based on location, morphology, and specific protein 
expression markers.  
Pericytes have multiple cytoplasmic processes which cover the abluminal surface of the 
endothelium (Figure 6), and pericytes have been shown to be of importance in blood vessel 
formation, blood flow regulation, maintenance of capillary integrity and permeability, and 
vascular remodeling (reviewed in Armulik et al., 2011).  
In the human lung, pericytes have been shown to be present in alveolar capillaries 
(transmission electron microscopic images in Weibel, 1974), where the pericytes have few 
and small processes. Recently, pericytes have been shown to be associated with development 
of pulmonary fibrosis (Hung et al., 2013) and pulmonary hypertension (Ricard et al., 2014, 
Yuan et al., 2015). However, the function of pericytes in the lung and the role in pulmonary 
vascular remodeling has not been fully determined.  
                                                                                     
Figure 6.  The illustration shows a pericyte 
which encircles the capillary endothelium 
and shares the basement membrane with the 
endothelium. 
 
Pericyte 
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Other vascular cell types  
The sections above mainly describe the role of ECs and mural cells in pulmonary vascular 
remodeling. It should however be noted that other cell types like fibroblasts, fibrocytes, 
inflammatory cells, and different types of progenitor cells also participate in vascular 
remodeling of PH and the role of these cells have been nicely reviewed elsewhere (Stenmark 
et al., 2012, Savai et al., 2012, Yeager et al., 2011).  
Extracellular matrix 
The extracellular matrix (ECM) of the vascular wall is the non-cellular component comprised 
of interstitial matrix and basement membranes. The vascular cells synthesize and release the 
ECM components, including fibrous proteins (e.g. elastin and collagen), glycoproteins (e.g. 
laminins), glycosaminoglycans, and proteoglycans. The ECM makes up a structural scaffold, 
but it also has versatile elastic properties of importance to protect the vessel against changes 
in mechanical forces. In addition, the ECM interacts with various chemokines, cytokines, 
growth factors, and cell-surface receptors to regulate cell adhesion, migration, differentiation 
and growth (reviewed in Mouw et al., 2014).  
The basement membrane is a specialized form of ECM which lies underneath the 
endothelium and separates the cell monolayer from the underlying connective tissue. 
Collagen IV, laminin, nidogen/entactin and perlecan are the major components of the 
basement membrane (LeBleu et al., 2007). SMCs in the vessel media are also surrounded by 
a basement membrane (Risau and Lemmon, 1988), which has been shown to play an 
essential role in the control of SMC phenotype and growth (Hedin et al., 1999). 
 
Elastin 
Elastin fibers form extensible elastic lamellae, essential for the elastic properties of large 
conduit arteries. The elastin precursor, tropoelastin, is a hydrophobic protein, which self-
associates by covalent cross-linking immediately after secretion to form elastic fibers with 
long-lasting capacity. In healthy vessels, the estimated half-life of elastin is 74 years (Shapiro 
et al., 1991). Elastin peptides are degradation products of elastic fibers and have been shown 
to be of importance in diseases such as atherosclerosis, diabetes, and aortic aneurysms 
(reviewed in Qin, 2015). It has also been shown that elastin degradation is associated with PH 
development (Todorovich-Hunter et al., 1988, Perkett et al., 1991). Loss of elastin contributes 
to increased stiffness of proximal pulmonary arteries (Lammers et al., 2008). Notably, 
increased activity of neutrophil elastase, the elastin degradation enzyme produced from 
neutrophils and PASMCs, has been linked to neointimal lesions in patients with PAH (Kim et 
al., 2011). It is likely that degradation of elastin in the ECM facilitates SMC proliferation and 
migration.  
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Collagen 
Collagens are the most abundant fibrous proteins in the body. Collagen IV is one of the 
principle components of basement membranes in the vascular wall. More than 20 years ago, 
it was observed that collagen synthesis is increased in different vascular lesions of PH 
(Botney et al., 1993). Recently, it was reported that increased procollagen levels are 
positively correlated with severity of disease in patients with PH (Safdar et al., 2014). 
 
Fibronectin 
Fibronectin is a large glycoprotein in the ECM. In addition to binding to integrins, fibronectin 
can interact with several ECM components such as collagen, fibrin, tenascin C and heparan 
sulfate proteoglycans. Increased fibronectin has been shown both in animal models of PH and 
in patients with PH (Durmowicz et al., 1994, Jones et al., 1997).  In addition, fibronectin can 
be serotonylated, which means that serotonin is attached to glutamine residues of fibronectin. 
Serotonylation has been show to promote pulmonary artery SMC proliferation and migration  
(Watts et al., 2009, Wei et al., 2012).  
 
Tenascin C 
Tenascin C is a glycoprotein in the ECM. Tenascin C can interact with fibronectin and inhibit 
fibronectin fibrillogenesis (Chung et al., 1995, To and Midwood, 2011). Increased tenascin C 
in neointima and obliterative lesions has been reported in patients with PH (Jones et al., 
1997). It has also been shown that loss of BMPR2 induces tenascin C production, which in 
turn promotes SMC proliferation (Ihida-Stansbury et al., 2006). 
 
 
Hyaluronan 
Hyaluronan is a large non-sulfated glycosaminoglycan synthesized on the plasma membrane 
and deposited in the ECM. Hyaluronan accumulates in plexiform lesions in patients with 
PAH (Aytekin et al., 2008), where hyaluronan binds to heavy chains of the plasma protein, 
inter-alpha-trypsin inhibitor, and forms a cable-like structure to faciliate leukocyte adhesion 
(Lauer et al., 2014).  
 
Inflammation  
A role of inflammation in PH was initially identified 20 years ago (Tuder et al., 1994). Since 
then, a large numbers of investigations, using both animal models and human material, have 
provided convincing evidence that inflammation plays a crucial role in PH development (see 
reviews, Price et al., 2012, Huertas et al., 2014, Rabinovitch et al., 2014). Dysregulation of T 
cells (mostly aberrant Treg function) and macrophage recruitment and activation are common 
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characteristics in vascular lesions of patients with PAH and in animal models of PH. 
Increased levels of autoantibodies and increased number of circulating dendritic cells have 
also been reported in several studies, but to a lesser extent. On the other hand, increased 
cytokines and chemokines, like IL-1-β, IL-6, IL-8, interferon-γ, and tumor necrosis factor-α, 
have been observed in patients with PAH and may be related to disease severity.  
 
120 years of research 
The earliest report of vascular lesions associated with PH can be traced back more than 120 
years. In 1891 a German physician, Ernst von Romberg, described a condition which he 
called “pulmonary vascular sclerosis” (Romberg, 1891). Since then, thousands of studies 
have been conducted to delineate the disease mechanisms in order to develop effective 
treatments. Endothelial dysfunction, excessive vascular remodeling, inflammation and in situ 
thrombosis are the major elements in the pathobiology of PH, and many cell types in the 
pulmonary vasculature take part in the remodeling process. The illustration below (Figure 7) 
shows the current understanding of the disease mechanisms.  
 
 
Figure 7. The pathogenic mechanisms of PH. Reprinted with permission (Schermuly et al., 
2011). 
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PROTEOGLYCANS 
Proteoglycans are complex molecules composed of a core protein with covalently bound 
linear polysaccharides called glycosaminoglycans (GAGs)  (Iozzo and Murdoch, 1996). The 
synthesis of core proteins takes place in the endoplasmic reticulum, followed by GAG 
synthesis and post-translational modifications in the Golgi apparatus (Prydz and Dalen, 
2000). After transport to the cell surface, the proteoglycans are either deposited in the ECM 
or retained at the cell surface.  
The GAGs of proteoglycans are polymerized and modified by glycosyltransferases, 
sulfotransferases and epimerases. Based on the structure of repeating disaccharide units, the 
sulfated GAGs can be heparan sulfate (HS), chondroitin sulfate (CS), dermatan sulfate (DS), 
or keratan sulfate. Heparin is a highly sulfated variant of HS. The basic disaccharide unit in 
HS is glucuronic acid linked to an N-acetylglucosamine residue, whereas CS comprises 
glucuronic acid and N-acetylgalactosamine (Figure 8). DS is similar to CS but contains in 
addition to glucuronic acid also its 5'-epimer iduronic acid. Keratan sulfate is a sulfated 
polymer of N-acetyl-lactosamine. 
 
 
Figure 8. Disaccharide units in GAGs. 
HS is a complex and heterogeneous structure of unbranched polysaccharide with various 
sulfation patterns and chain lengths. The synthesis of HS chains is initiated by the formation 
of a tetrasaccharide linkage region on selected serine residues of core proteins, followed by 
transfer of the first N-acetylglucosamine residue to the linkage region and stepwise addition 
of glucuronic acid and N-acetylglucosamine. The extended chains are further modified by 
sulfotransferases and an epimerase (Kreuger and Kjellen, 2012).  
HS chains have diverse functions, including modulation of mitogen and morphogen signaling 
(Jastrebova et al., 2006), clearance and retention of lipoproteins (MacArthur et al., 2007, 
Tran-Lundmark et al., 2008), direction of neutrophil infiltration (Wang et al., 2005), 
stimulation of appetite (Reizes et al., 2001), and facilitation of amyloid deposition 
(Scholefield et al., 2003). It has been proposed that the overall negative charge density on HS 
chains determines the interaction between HS and proteins (see reviews, Bishop et al., 2007, 
Lindahl and Kjellen, 2013).  
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Like HS, CS chains also have variable sulfation patterns and may possess many different 
biological activities. CS-protein interactions are possible through electrostatic charge, similar 
to HS-protein interactions. However, the function and actual mechanisms have not been as 
well characterized as those for HS.   
In general, proteoglycans are widely expressed on the cell surface and in the ECM. An 
exception is serglycin, which is found in the secretory granules of mast cells and other 
myeloid cells. Studies over the past 40 years have revealed that proteoglycans not only take 
part in ECM assembly, but also play pivotal roles in cell adhesion, proliferation, migration, 
and differentiation during embryonic development and tissue remodeling (reviewed in Iozzo 
and Schaefer, 2015).  
The following sections describe some important proteoglycans in the vascular wall.  
Perlecan 
Perlecan is the largest heparan sulfate proteoglycan (HSPG) and the major HSPG in the 
basement membrane. It was initially isolated from the basement membrane of the Engelbreth-
Holm-Swarm sarcoma and obtained the name based on the ultrastructural feature of “beads 
on a string” revealed by rotary shadowing electron microscopy (Hassell et al., 1980, Paulsson 
et al., 1987, Yurchenco et al., 1987).  Complete sequencing and protein structure 
characterization have demonstrated that this macromolecule (~800 kDa) contains 5 globular 
domains with 4391 amino acids (~470 kDa) and 3 HS chains attached to the N-terminus and 
one chain to the C-terminus (Figure 9) (Noonan et al., 1991, Murdoch et al., 1992, Cohen et 
al., 1993). 
 
 
Figure 9. Schematic illustration of perlecan. Domain I contains three Ser-Gly-Asp triplets 
that are HS binding sites. The additional HS binding site in domain V is not shown in this 
picture. Reprinted with permission (Iozzo, 2005).  
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In blood vessels, perlecan is synthesized by ECs and SMCs, and deposited in basement 
membranes. Perlecan is not only part of the ECM scaffold, but also acts as a modulator for 
growth factors. The heparan sulfate (HS) chains linked to domain I are able to bind various 
growth factors (e.g. FGF, VEGF, PDGF) (Ornitz, 2000, Knox et al., 2002, Zoeller et al., 
2009, Ishijima et al., 2012) and function as modulator by presenting the growth factors to the 
cognate signaling receptors or by sequestering growth factors for storage (Figure 10). In 
addition, the negative charge of HS takes part in maintenance of gradients for mitogens and 
morphogens in the extracellular space (Abramsson et al., 2007). 
In vascular biology, perlecan HS has been shown to inhibit SMC proliferation in vitro 
through hampering FGF-2 activity (Nugent et al., 1993, Forsten et al., 1997). Our group has 
previously shown that perlecan HS inhibits intimal hyperplasia in the carotid ligation model, 
possibly through sequestering FGF-2 in the ECM (Tran et al., 2004). On the other hand, 
perlecan HS can serve as a functional docking platform for FGF-2. A recent study showed 
that perlecan is upregulated in neointima lesions in the renal transplantation model in which 
perlecan HS promotes FGF-2 activity (Katta et al., 2013). Perlecan HS also promotes 
angiogenesis by formation of the perlecan/FGF-2 complex resistant to proteolysis (Saksela 
and Rifkin, 1990, Aviezer et al., 1994), or by maintenance of the basement membrane 
integrity (Stratman et al., 2009, Gustafsson et al., 2013).   It has been reported that perlecan 
HS derived from different cell types modulate FGF signaling in different ways (Knox et al., 
2002, Lord et al., 2014). The dual function of perlecan HS may imply the presence of 
different HS structures due to cell type specific post-translational modifications.  
 
 
Figure 10. The duality of perlecan HS. (A)Perlecan HS chains sequester FGFs to inhibit 
FGFs activity (B) Perlecan HS chains function as a docking platform for FGFs to promote 
signaling.    
 
While HS chains on the N-terminal have pro-angiogenic properties, the C-terminal of 
perlecan harbors anti-angiogenic properties. Endorepellin, a fragment from the C-terminal of 
perlecan containing three laminin-like globular domains, has been shown to inhibit 
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angiogenesis via binding to the α2β1 integrin and to VEGF receptor 2, which in turn 
suppresses HIF-1α and NFAT activity (Mongiat et al., 2003, Goyal et al., 2012). 
Endorepellin can be cleaved by the BMP-1/Tolloid proteases, releasing the LG3 domain with 
potent angiostatic activity (Gonzalez et al., 2005, Le et al., 2011). On the other hand, LG3 
facilitates SMC migration and is associated with neointima formation after renal allograft 
transplantation (Soulez et al., 2012). 
Syndecans 
Syndecans are cell surface HSPGs with transmembrane domains (Figure 11). In addition to 
HS, CS GAG chains may also be attached to the syndecan core proteins. In vertebrates, there 
are four syndecan members (syndecan-1, -2, -3, and -4) expressed by distinct genes on 
different chromosomes. Syndecans are important regulators for cell-cell and cell-matrix 
interactions. In addition, syndecans like other HSPGs can modulate growth factor signaling. 
Syndecan-1 has been shown to inhibit intimal hyperplasia and keep SMCs in a differentiated 
and quiescent state (Fukai et al., 2009, Chaterji et al., 2014).  
Figure 11. Syndecan                     
 
Glypicans 
Glypicans are cell surface HSPGs that are linked to the cell membrane by a 
glycosylphosphatidylinositol anchor (Figure 12). In mammals, six glypicans (GPC1-GPC6) 
have been identified. Glypicans have been shown to modulate the activity of FGFs, Wnt, and 
Hedgehog (Gutierrez and Brandan, 2010, Capurro et al., 2005, Capurro et al., 2008). 
Glypican-3 deficient mice display developmental overgrowth and cardiac malformation, 
suggesting that glypican-3 is important for developmental morphogenesis (Ng et al., 2009).  
Figure 12. Glypican                       
 
HS/CS 
HS 
GPI Anchor 
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Versican 
Versican is the largest chondroitin sulfate proteoglycan (CSPG) in the ECM. The eponym, 
versican, comes from its versatile function and complex structure (Zimmermann and 
Ruoslahti, 1989). Versican exists in at least four isoforms, V0, V1, V2, and V3. The full 
length versican core protein (V0) has a molecular weight of around 400 kDa with 3396 amino 
acid residues and is composed of  the G1domain at the N-terminus, the αGAG domain 
(encoded by exon 7) and the βGAG domain (encoded by exon 8) in the central region with 
CS attachment sites, and the G3 domain at the C-terminus. Alternative splicing of the GAG 
attachment domains generates at least 3 additional isoforms, V1 (with βGAG domain), V2 
(with αGAG domain), and V3 (no GAG binding domain) (Figure 13) (Naso et al., 1994). V0 
and V1 isoforms are present in the developing heart and in vascular SMCs (Yao et al., 1994), 
V2 is a major component of the ECM which surrounds myelinated fibers in the brain 
(Schmalfeldt et al., 1998).  
 
Figure 13. Schematic model of the versican core protein and its isoforms. Versican has two 
globular domains, the G1 domain at the amino terminus and the G3 domain at the carboxy 
terminus. The splice variants vary in the GAG attachment domains (αGAG and βGAG). Ig: 
immunoglobulin-like domain; HABR: hyaluronan binding region; E: epidermal growth 
factor-like domain; L: lectin binding domain and C: complement regulatory region. Dashes 
represent CS chains. 
In general, versican protein levels are low in connective tissue and increase in various 
pathological conditions (reviewed in Theocharis, 2008). By binding to molecules like growth 
factors, chemokines and ECM proteins, versican takes part in diverse biological activities 
through regulating cell adhesion, migration, proliferation and differentiation. 
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 A large number of studies have demonstrated that versican accumulates in vascular diseases 
like atherosclerosis and restenosis, where versican is essential for SMC growth, lipoprotein 
retention, and retention of inflammatory cytokines (reviewed in Wight and Merrilees, 2004). 
For example, the N-terminal of versican can bind to hyaluronan and form large aggregates in 
the ECM, which have been shown to increase SMC proliferation and migration as well as to 
retain leukocytes in the ECM (LeBaron et al., 1992, Evanko et al., 1999, Evanko et al., 2012). 
On the other hand, the V3 variant has been shown to inhibit SMC proliferation. In addition, 
versican with CS chains may directly or indirectly disturb elastin synthesis and elastic fiber 
formation (Merrilees et al., 2011).  
 
Decorin 
Decorin is one of the small leucine-rich proteoglycans (Figure 14). The eponym was coined 
based on its ability to decorate collagen fibrils near the D band (Krusius and Ruoslahti, 1986, 
Pringle and Dodd, 1990, Fleischmajer et al., 1991). In addition to regulating collagen fibril 
formation, decorin is able to control cell growth through interacting with many growth factors 
and growth factor receptors. For example, decorin can inhibit proliferation by inducing EGF 
receptor internalization and degradation (Zhu et al., 2005). It has also been shown to suppress 
HIF-1α and VEGFA (Neill et al., 2012).  
In the lung, decorin inhibits TGF-β activity, which in turn reduces pulmonary fibrosis (Kolb 
et al., 2001). In vascular pathology, decorin has been shown to be deposited prominently in 
the ECM of the fibrous cap of atherosclerotic plaque, where there is collagen accumulation 
(Radhakrishnamurthy et al., 1998). Cyclic mechanical strain on aortic SMC reduces decorin 
production while versican is upregulated (Lee et al., 2001). Interestingly, it has been 
demonstrated that decorin gene delivery reduces cardiac fibrosis in hypertensive rats (Yan et 
al., 2009) and inhibits neointima formation in an ex vivo model of venous grafting (Ranjzad et 
al., 2009).  
 
                Figure 14. Decorin        
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Biglycan 
Biglycan is also one of the small leucine-rich proteoglycans in the ECM. It is structurally 
similar to decorin with > 65% overall homology (Figure 15). In atherosclerosis, biglycan 
prominently accumulates in the intima and co-localizes with versican (Lin et al., 1996). 
Biglycan has been shown to promote SMC proliferation and migration (Shimizu-Hirota et al., 
2004). Furthermore, the GAG chains of biglycan take part in lipid retention (O'Brien et al., 
2004). Recently, increased atherosclerosis development was reported in mice with SMC-
specific biglycan overexpression (Thompson et al., 2014). However, biglycan-deficient mice 
are not protected against atherosclerosis. Instead, the mice are predisposed to angiotensin II-
induced aortic aneurysm formation, concomitant with increased vascular perlecan content 
(Tang et al., 2014). 
 
                                                                      
 
 
The two largest proteoglycans in the extracellular matrix, perlecan and versican, are the main 
focus of this thesis (Paper II and III). The role of perlecan and versican in vascular 
remodeling in PH are discussed in the “Results and Discussion” section.  
 
  
Figure 15. Biglycan. The eponym was 
coined because this proteoglycan 
contain two GAG chains.  
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AIM OF THE STUDY 
 
As mentioned in the “Introduction” section, current treatments for PH with endothelin 
receptor antagonists, prostacyclin analogues, and PDE-5 inhibitors have limited effects on the 
long-term outcome and the 5-year mortality rates for patients with PH are still high, ranging 
from 40%-80% (Thenappan et al., 2012). More research is therefore needed to find better 
diagnostic tools and better pharmacological treatments, especially targeting excessive 
vascular cell proliferation. Deeper insight into the vascular remodeling of PH is required to 
design new pharmacological therapies. 
The general aim of this thesis was to study the regulation of SMC growth and the role of 
ECM proteoglycans in vascular remodeling in PH.  
The specific aims were: 
Paper I: To investigate the effect of imatinib on pulmonary vascular remodeling associated 
with congenital diaphragmatic hernia.  
Paper II: To study the role of basement membrane perlecan HS in the vascular remodeling 
process of hypoxia-induced PH. 
Paper III: To explore the role of versican, the major CSPG in the vascular ECM, in vascular 
lesions of PAH.  
Paper IV: To examine the role of the PDGF-B retention motif in pulmonary vascular 
remodeling in hypoxia-induced PH. 
 
 
 
 
 
 
 
 
 
 
  
 24 
 
 
  
 25 
 
MATERIALS AND METHODS 
 
PRECLINICAL MODELS OF PULMONARY HYPERTENSION 
PH is a devastating vascular disorder. In order to investigate the pathobiology and design 
effective pharmacological therapies, several animal models of PH have been established 
during the past decades. The use of animal models allows us to study the disease progress at 
different time points. This approach provides valuable insight into pathogenic mechanisms 
and also benefits innovation of pharmacological agents. 
Chronic hypoxia 
Chronic hypoxia exposure (10% O2) can be used to induce vascular remodeling in many 
different species (e.g. mice, rats, and calves) and it is the most commonly used model, while 
monocrotaline injection is widely used in rats to induce PH. The advantage of the chronic 
hypoxia model is the simplicity and reproducibility. The vascular changes seen comprise 
distal muscularization of normally nonmuscularized intra-acinar arterioles, thickening of the 
tunica media, adventitial fibrosis, and perivascular inflammatory infiltration (Rabinovitch et 
al., 1979, Stenmark et al., 2006). In addition, ECM remodeling and stiffening of proximal 
conduit pulmonary arteries have been observed (Lammers et al., 2008, Ooi et al., 2010). In 
general, the vascular remodeling seen with hypoxia, especially in mice, is not severe and 
there is no neointima formation and no plexiform lesions (Stenmark et al., 2006). Since the 
initial insult is alveolar hypoxia, reversal of the vascular remodeling can be observed 
following increase of oxygen back to normal level (21% O2). However, the reversal process 
can be slow and incomplete following long-term hypoxia exposure (Rabinovitch et al., 1981, 
Li et al., 2004).   
Chronic hypoxia with sugen (SU5416) 
Chronic hypoxia combined with sugen, a VEGF inhibitor, was developed to recapitulate 
more severe and obliterative vascular lesions in human PH (Taraseviciene-Stewart et al., 
2001). In rats, a single dose of subcutaneous SU5416 (20 mg/kg) followed by 3 weeks of 
hypoxia induces proliferation of apoptosis-resistant ECs accompanied by near-complete 
lumen obliteration of medium-sized and intra-acinar arteries. In addition, when the rats are re-
exposed to normoxia for an additional 10-11 weeks, plexiform-like lesions and decreased 
cardiac output can be observed (Oka et al., 2007, Abe et al., 2010).  
In contrast, a single dose of SU5416 combined with chronic hypoxia is not enough to induce 
severe PH lesions in mice, possibly due to different metabolism in mice compared to rats. It 
has been reported that 20 mg/kg of SU5416 once weekly, subcutaneously or intraperitoneally, 
combined with 3 weeks of chronic hypoxia can be used to induce severe PH with concentric 
neointimal thickening and occlusion in arterioles in mice (Ciuclan et al., 2011, Wang et al., 
2013). However, following return to normoxia there is no PH progression but instead 
 26 
 
decreased medial wall thickening and decreased right ventricular hypertrophy. (Wang et al., 
2013, Vitali et al., 2014). 
Monocrotaline 
Monocrotaline is a toxic pyrrolizidine alkaloid derived from the plant Crotalaria spectabilis. 
Following processing by cytochrome P-450 (CYP3A4) in the liver it becomes a reactive 
metabolite (Wilson et al., 1992, Kasahara et al., 1997), which enters the circulation and 
causes endothelial dysfunction (Schultze and Roth, 1998) and acute pulmonary vasculitis 
(Chesney and Allen, 1973). In rats a single dose of subcutaneous or intraperitoneal 
monocrotaline (40-80 mg/kg) induces vascular wall thickening, PH and right ventricular 
hypertrophy, but no occlusive vascular lesions. Notably, myocarditis (Akhavein et al., 1985, 
Gomez-Arroyo et al., 2012b) with prominent lymphocyte infiltration has also been found in 
this model. High pulmonary artery pressure may therefore not be the only cause of morbidity 
and mortality in this model.  
It should be noted that monocrotaline is a toxin which causes toxicity not only to pulmonary 
vessels and myocardium, but also to liver (Perazzo et al., 1999) and neurons (Silva-Neto et 
al., 2010). In addition, some pharmacological agents which can reverse monocrotaline-
induced PH in rats have no effect in human PH (reviewed in Stenmark et al., 2009). This 
model is therefore suboptimal for testing new drugs.  
Other preclinical models 
In addition to the chronic hypoxia and monocrotaline model, genetically modified mouse 
models of PH are available, in which mice develop PH spontaneously due to either loss of 
function or overexpression of a specific gene. These models enable us to study distinct 
molecular pathways in vivo and have been discussed in the following reviews (Stenmark et 
al., 2009, Ryan et al., 2011, Gomez-Arroyo et al., 2012a).  
Unfortunately, the perfect animal model for human PH is not yet available. However, some 
pathobiological responses in the animals share common pathways with human PH thus 
providing us clues in the search for effective treatments. Table 2 summarizes the similarity of 
each commonly used animal model of PH.   
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Table 2. Comparisons of pathophysiologic findings in the commonly used PH models  
Stimuli Chronic 
hypoxia 
Chronic 
hypoxia 
Chronic 
hypoxia 
with sugen 
Chronic 
hypoxia 
with sugen 
Monocrotaline 
Species Mouse Rat Mouse Rat Rat 
Vascular remodeling      
Neointima No No Yes Yes Yes 
Medial hypertrophy Yes Yes Yes Yes Yes 
Adventitial fibrosis Yes Yes Yes Yes Yes 
Plexiform formation 
 /obliterative lesions 
No No Yes Yes No 
Perivascular 
inflammation 
Yes Yes Yes Yes Yes 
Increased RVSP Yes Yes Yes Yes Yes 
Disease progression      
RV hypertrophy Yes Yes Yes Yes Yes 
RV dysfunction 
 /RV failure* 
? Yes Yes Yes No (40 mg/kg) 
Disease reversibility 
following removal of 
stimuli 
? Irreversible 
RV 
dysfunction 
(Bonnet et 
al., 2004) 
Reversible 
(Vitali et al., 
2014) 
Irreversible 
(Abe et al., 
2010)  
40 mg/kg: 
reversible 
(Ruiter et al., 
2013) 
≥ 60 mg/kg: 
high mortality  
RV: right ventricle; RVSP: right ventricular systolic pressure 
?: Not known 
*Defined by decreased RV compliance, decreased RV contractility, or decreased cardiac output 
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RAT MODEL OF NITROFEN-INDUCED CONGENITAL 
DIAPHRAGMATIC HERNIA (PAPER I) 
Congenital diaphragmatic hernia (CDH) is a severe life-threatening malformation of the 
diaphragm characterized by herniation of the abdominal viscera to the chest cavity and 
accompanied with pulmonary hypoplasia and pulmonary hypertension (Badillo and 
Gingalewski, 2014). The persistent pulmonary hypertension and pulmonary hypoplasia lead 
to respiratory failure in the newborns with CDH.  
The nitrofen-induced rat model of CDH is the most commonly used preclinical model for 
studies of the pathogenic mechanisms. The offspring of nitrofen treated rats have 
diaphragmatic defects, pulmonary hypoplasia, and pulmonary vascular remodeling similar to 
human CDH (Costlow and Manson, 1981, Newell et al., 1998, Okoye et al., 1998, Luong et 
al., 2011). Although the actual mechanism of CDH is not fully understood, it has been shown 
that nitrofen (2,4-dichloro-1-(4-nitrophenoxy)benzene), a teratogenic herbicide, disturbs the 
retinoic acid pathway during organogenesis (Greer et al., 2003), and inhibits growth of the 
pleuroperitoneal folds (Clugston et al., 2010).   
Clinically, newborns with CDH have a high risk of acute right heart failure when the PH is 
not responsive to inhaled nitric oxide under optimized ventilatory support (Mohseni-Bod and 
Bohn, 2007). In addition, continued PH or recurrence of PH after surgical correction causes 
significant morbidity and mortality in CDH patients (Peetsold et al., 2009).  
A previous case report from our collaborators had described successful use of imatinib in a 
neonate with CDH and severe PH (Frenckner et al., 2008).  We therefore hypothesized that 
antenatal treatment targeting pulmonary vascular remodeling/PH in CDH could be beneficial 
and possibly reduce the need for extracorporeal membrane oxygenation (ECMO) in the 
neonatal period. The aim of paper I was to explore the effect of prenatal PDGF inhibition on 
pulmonary vascular remodeling in CDH. CDH was induced by oral administration of nitrofen 
(100 mg in 1 ml of olive oil) to pregnant rat dams on gestational day 9.5 (Kluth et al., 1990).  
At birth, approximately 60%-70% of the pups developed CDH. Imatinib was used for PDGF 
inhibition (Figure 16).  
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(A)    Pregnant Sprague-Dawley rats  
 
          
 (B)             
 
 
Figure 16. (A) Timeline for the use of imatinib in paper I. (B) Methods for analysis of 
pulmonary vascular remodeling. 
 
 
 
 
 
 
Gestational day E17 E18 E19 E20 E21   E9.5
Nitrofen Imatinib 50 mg/kg 
Nitrofen NaCl
Imatinib 50 mg/kg 
Olive oil NaCl
Group I
Group 2
Group 3
Group 4
Olive oil
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CHRONIC HYPOXIA MODEL (PAPER II AND PAPER IV) 
Chronic hypoxia exposure (10 % O2) is a relevant model for the hypoxia-induced vascular 
remodeling seen predominantly in group III PH (secondary to other lung diseases). However, 
since the aim of many studies is to explore the mechanisms which govern the increase in 
vascular muscularization seen in PH, independent of underlying etiologies, chronic hypoxia 
model is still widely used due to its simplicity and reproducibility. It is often beneficial to use 
a mouse model because of access to relevant transgenic mouse strains, lacking or 
overexpressing a gene of interest. A schematic diagram for the setup of the hypoxic cabinet 
(Coy laboratory products, USA) used in paper II and paper IV is shown below (Figure 17). 
 
         
 
 
 
 
 
Even though the hypoxia-induced PH model has been used for more than 30 years, the data 
regarding the exact time course of pulmonary vascular remodeling and right ventricular 
remodeling is still lacking. This may be owing to the difference in the response to hypoxia 
between species and there are also variances between strains (Tada et al., 2008). For example, 
calves usually develop more severe PH than rats, and rats develop more severe PH than mice 
(Stenmark et al., 2009). In addition, age and gender are also important factors (Rabinovitch et 
al., 1981). Younger mice and rats usually develop higher PH than elder ones and males have 
higher RVSP than females. The approximate timing of major events during development of 
hypoxia-induced PH is described below (Table 3).  
De
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m
id
ifi
er
 
Fan 
O2 
cylinder 
N2 
cylinder 
Active carbon 
Carbolime 
O2 controller 
CO2 controller 
Figure 17. Hypoxic cabinet 
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Table 3.  Timeline of hypoxic PH development for C57BL/6 mice  
 Day 0  
 Day 3-7 Prominent SMC migration and proliferation (White et al., 2010, Sheikh et al., 2014) 
 Day 7 Gradual decrease of SMC proliferation to baseline level (Sheikh et al., 2014) 
  
 
 
 
 3 week Appearance of increased RVSP and RV hypertrophy (Zhao et al., 2001) 
 4-6 week Slow increase of RVSP and RV hypertrophy (Li et al., 2009) 
 7-10 week PH reaches a plateau, no deterioration? (Our pilot experiments) 
 
           
To confirm that the mice have been adequately exposed to hypoxia, blood samples can be 
drawn from the right ventricle to check hemoglobin levels. Increased hemoglobin levels 
indicate the presence of physiologic polycythemia and successful hypoxia exposure. To 
evaluate the severity of PH, we routinely perform morphometric analysis of pulmonary 
vascular remodeling/increase in muscularization, RVSP measurements, and obtain the Fulton 
ratio (defined by the dry weight ratio of the right ventricle to the left ventricle plus 
interventricular septum, as an index of right ventricular hypertrophy). Several studies of 
genetically modified mice have revealed that these three parameters, increased vascular 
muscularization, increased RVSP, and increased Fulton ratio, are not always present 
concomitantly following chronic hypoxia (Stenmark et al., 2009, Gomez-Arroyo et al., 
2012a).  
Measurement of right ventricular systolic pressure 
Following hypoxia treatment we induce anesthesia with 3% isoflurane and 1.5% isoflurane is 
maintained for right heart catheterization. A closed-chest approach is used since open-chest 
methods require endotracheal incubation and mechanical ventilation, factors which would 
influence the pressure measurements. Following right jugular vein cannulation, a 1.4 French 
Micro-Tip pressure catheter connected to a transducer (Model SPR-671, Millar) is advanced 
into the right ventricle. By observing the shape of the pressure curve on the display of the 
data acquisition system we can determine the localization of the catheter tip and be sure that it 
has passed the right atrium and is correctly placed in the right ventricular chamber. 
Continuous pressure recording (for 2-3 min) for each mouse is necessary for reliable data 
collection for further analysis. 
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It is important to maintain the same anesthetic conditions and the same procedure duration 
(usually 10 min) for each mouse. Higher concentration of the anesthetic agent or longer 
duration will reduce the RVSP and induce bradycardia.  
Tissue preparation and morphometric analysis 
Mice have four lobes in the right lung and one big lobe in the left. Therefore, we prefer to use 
the left lung for histology and the right lung for RNA and protein extraction. For histology, 
the pulmonary circulation is flushed with PBS through the right ventricle until the blood 
completely comes out from the opening of thoracic aorta. The lungs are then perfusion fixed 
with 4% zinc-formaldehyde via the right ventricle, while being kept inflated with zinc-
formaldehyde infusion via the trachea.    
Since the pulmonary vasculature has multiple branching points like a tree a large number of 
tissue sections are required for a systematic and reliable morphometric analysis, especially for 
quantification of distal vascular muscularization.  
Imaging the pulmonary vasculature  
Several imaging techniques can be applied to study the structural changes in PH. Barium 
injection combined with micro-CT (computed tomography) (Vitali et al., 2014) has recently 
been described as a way to visualize pulmonary arterioles three-dimensionally,  since barium 
cannot pass through the capillary network. MICROFIL injection is another alternative for 
post-mortem analysis (Sullivan et al., 2003, Li et al., 2009). Electron microscopy can also 
provide extensive structural information on the single cell level (Li et al., 2009).  
In vivo X-ray angiography is difficult to perform in mice since the image acquisition rate is 
not as fast as the murine heart rate (450-750 beats per minute). However, with improved 
resolution and the possibility to choose a specific phase of contrast filling for image analysis 
(e.g. arterial phase or venous phase) angiography can be a useful tool for obtaining 
information from live animals. 
Other methods can also be used. For example, cardiac echo is a non-invasive method which 
can be used to monitor hemodynamic changes over time in the same animal (Thibault et al., 
2010). Intravital microscopy makes it possible to observe dynamic cell-cell interactions in the 
pulmonary microcirculation (Tabuchi et al., 2008). Optical projection tomography, 
ultrasound biomicroscopy and many other developing  techniques will open new imaging 
possibilities for studies of pulmonary vascular remodeling as well as right ventricular 
remodeling in murine models of PH (Powell and Wilson, 2012).  
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MOUSE STRAINS 
Perlecan mutant mice (Hspg2Δ3/Δ3) 
Hspg2Δ3/Δ3 mice were generated by target deletion of exon 3 of the perlecan gene, which 
results in loss of HS attachment sites in domain I of perlecan (Rossi et al., 2003). The mice 
were kindly provided by Prof Karl Tryggvason and Prof Raija Soininen, Karolinska Institutet 
and University of Oulu. 
Initially, the mice were generated for studies of kidney physiology and disease. Based on the 
negative charge and hydrophilic properties of HS, researchers hypothesized that perlecan HS 
in the glomerular basement membrane would function as a permeability barrier for 
macromolecules (Kanwar and Farquhar, 1979). However, the Hspg2Δ3/Δ3 mice did not have 
proteinuria (unless aggressively challenged). Instead, the perlecan mutant mice were noted to 
develop cataract due to increased apoptosis in the epithelial cell layer of the lens.  
Hspg2Δ3/Δ3 mice are vital and fertile, whereas a perlecan-null mutation is lethal (Arikawa-
Hirasawa et al., 2002, Costell et al., 2002). The Hspg2Δ3/Δ3 mice are a useful tool to study the 
function of N-terminal HS. Previously, our group has used the mice to investigate the role of 
perlecan HS in intimal hyperplasia and atherosclerosis. In the carotid ligation model, 
Hspg2Δ3/Δ3 mice developed more intimal hyperplasia than wild-type mice, possibly due to 
defective FGF-2 sequestration (Tran et al., 2004). In atherosclerosis, Hspg2Δ3/Δ3 mice cross-
bred with apoE null mice developed less atherosclerosis than apoE null control mice, possibly 
due to decreased lipid retention (Tran-Lundmark et al., 2008).  
In paper II, we used Hspg2Δ3/Δ3 mice to study the role of perlecan HS in vascular remodeling 
in PH. To rule out the observed effects associated with other genes within the background, 
backcross breeding to C57BL/6 was performed for at least 10 generations. Genotyping was 
routinely performed. At the endpoint of every experiment ear biopsies were also taken for 
genotyping to confirm the correct genotype.  
PDGF-B retention motif knockout mice (Pdgfbret/ret) 
Pdgfbret/ret mice were kindly provided by Prof Christer Betsholtz at Karolinska Institutet. The 
mice were generated for studies of the biological function of the PDGF-B retention motif, a 
C-terminal region of PDGF-B with repeated basic amino acid residues. At physiological pH, 
the basic amino acids are protonated and the positive charge can interact with negatively 
charged HS. This electrostatic interaction is important for maintaining PDGF-B gradients in 
the ECM during angiogenesis (Lindblom et al., 2003, Abramsson et al., 2007, Stenzel et al., 
2009) and may also be of importance in pathological states like PH.  
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Pdgfbret/ret mice were generated by insertion of TAA stop codon into exon 6 of the PDGF-B 
gene, resulting in loss of the C-terminal retention motif (Lindblom et al., 2003). Pdgfbret/ret 
mice are vital but show impaired pericyte investment into the microvessels, reduced number 
of renal mesangial cells, albuminuria, and retinopathy. PDGF-B levels in Pdgfbret/ret 
endothelial cells are lower compared to wild-type control. In paper IV, we used Pdgfbret/ret 
mice to study the role of the PDGF-B retention motif in vascular remodeling in PH.  
PROTEOGLYCAN ANALYSIS 
Metabolic labeling of proteoglycans in vitro 
Metabolic labeling with [35S]sulfate is the most commonly used method for studying 
endogenous synthesis of proteoglycans, in which cells incorporate [35S]sulfate into the newly 
produced GAGs.  In paper III, human PASMCs were grown for 3 to 4 days in M231 growth 
medium containing 5% fetal bovine serum and other growth promoting factors. The medium 
was then changed to DMEM medium containing 0.4% fetal bovine serum for the 6 hours of 
metabolic labeling with [35S]sulfate. Medium with low content of sulfate (e.g. MgSO4) is 
recommended to increase the yield of labeled proteoglycans.  
Following metabolic labeling, medium samples were collected, and cell layer samples were 
extracted with solubilization buffer (50 mM Tris-HCl pH 7.5, 1% Triton X-100, 0.15 M 
NaCl) containing a protease inhibitor cocktail. The proteoglycans were then purified by 
DEAE (Diethylaminoethyl)-Sephacel anion-exchange chromatography. During the anion-
exchange process the pH was changed from pH 8 to pH 4. In those conditions most proteins 
lose their negative charge, whereas the GAG chains of the proteoglycans keep the charge 
and continue to bind to the positively charged gel beads. Thereby we were able to separate 
proteoglycans from other proteins.  
The purified intact proteoglycans were then analyzed by gel filtration chromatography. To 
analyze GAGs, alkaline treatment with 0.5M NaOH overnight at 4 ºC was used to release 
GAGs from their core proteins. The samples were then applied on NAP-10 column packed 
with Sephadex G-25 for desalting. In order to analyze the proportion of HS and CS in the 
GAG preparations, chondroitinase ABC was used to digest CS/DS. Since a high salt 
content in the samples will interfere with the enzymatic activity of chondroitinase ABC, the 
desalting step prior to digestion is necessary.  
Gel filtration chromatography 
Gel filtration chromatography, or molecular sieve chromatography, is a classic method which 
can separate molecules by size. Here we used Sephadex G50 to separate undigested HS from 
CS degradation products following chondroitinase treatment, Superose 6 to analyze length of 
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GAGs, and Sepharose CL-2B for size separation of intact proteoglycans. The choice of 
polymer is based on the molecular weight of the molecules in the sample since the separation 
ranges are different. In the chromatography columns, the molecules of larger hydrodynamic 
size will pass the porous gel matrix faster, thus appearing in the fractions which elute first, 
and the smaller molecules will travel through the porous gel matrix slower thus eluting later.  
By using Sepharose CL-2B chromatography, we can see changes in hydrodynamic size of 
intact proteoglycans, which is the result of changes in the size of core protein, changes in the 
length of GAGs or of the number of GAG chains attached to the core protein (or any 
combination of the three). The results from Superose 6 chromatography can provide distinct 
information on changes in the length of GAG chains. 
Proteoglycan extraction from lung tissue and Western blot 
In order to study the content of specific proteoglycans in lung tissue, proteoglycans were 
extracted from homogenized tissue with 4M guanidine buffer (4M guanidine HCl, 100 mM 
sodium sulfate, 100 mM Tris-base, 2.5 mM Na2EDTA, 0.5% Triton X-100, pH7.0). Before 
proteoglycan purification by DEAE-Sephacel ion-exchange chromatography, the samples 
were dialyzed extensively against 7M urea buffer (7M urea, 50 mM Tris-base, 2 mM 
EDTA, 0.5% Triton X-100, pH 7.5) to remove guanidine. Since guanidine is a chaotropic 
agent with high ionic strength, it would shield the electrostatic interactions of proteoglycans 
with the DEAE-Sephacel column.  
Following measurement of protein concentration by Bradford protein assay, samples 
containing equal amounts of protein were used for DEAE-Sephacel ion-exchange 
chromatography. 8M urea buffer (8M urea, 50 mM Tris-base, 2 mM EDTA, 0.5% Triton 
X-100, pH 7.5) with 0.25M NaCl was used for equilibration and washing of the column, 
and the samples were then eluted with 8M urea buffer containing 2M NaCl.  
Ethanol precipitation (1.3% potassium acetate in 95% ethanol) at -20 °C for 2 h was then 
performed 2-3 times to remove urea and detergents. For the first ethanol precipitation, CS 
(5 µg/mL) was added as a carrier. After air-drying the samples, chondroitinase ABC in 
chondroitinase buffer (50 mM Tris-HCl, 30 mM sodium acetate, 0.1% BSA, pH 8.0) was 
added and the samples were incubated at 37 ºC for 3 h. Enzymes for deglycosylation can be 
chondroitinase ABC, heparinase, or both, depending on the subclasses of proteoglycans of 
interest. Enzymatic deglycosylation facilitates the entry of proteoglycans into the gels for 
SDS-PAGE, making it possible to estimate the size of the core proteins.  
For Western blot, the samples were reduced and applied on a 3.5% stacking gel with a 4-
12% resolving gel for SDS-PAGE. Proteins were then transferred to nitrocellulose 
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membranes using a Bio-Rad Transblot SD Semi-Dry Transfer Cell. Immunoblotting was 
performed according to standard protocols.  
By looking for the shift in molecular weight following different types of enzyme treatment, 
it is possible to determine the composition of GAGs attached to a certain proteoglycan. 
Intact proteoglycans will appear as smear on Western blots because of variable sizes of 
GAGs. If the smear turns to a discrete band following chondroitinase treatment, this 
indicates that the GAGs are CS/DS, and not HS.  
Summary 
In general, to study proteoglycan content in tissue is a challenging task. The available assays 
are still mainly antibody-based methods, like immunohistochemistry, immunoprecipitation, 
and Western blot. Immunohistochemistry gives information about localization in the tissue, 
but is not good for quantification. Western blot is often used for quantification, but requires 
purification/concentration of the samples and is challenging because of the large size of 
extracellular proteoglycans. All antibody based methods also requires high specificity of the 
antibodies and often pretreatment of the tissue or the samples with GAG lyases (so that the 
antibody can reach the core protein). In situ hybridization provides data on gene expression, 
but may not reveal the presence of different core protein isoforms and does not give 
information about the sulfation patterns of GAGs. To investigate the biological function of a 
certain proteoglycan, in vitro studies of proteoglycans extracted from the cell cultures and 
genetically modified mice are the most commonly used methods.  
PRIMARY CELL ISOLATION FOR SMC CULTURES 
The technique of tissue culture was introduced more than 100 years ago (Harrison, 1907, 
Rous and Jones, 1916). Since then, cell behavior can be observed in a controlled 
environment. Methods for isolating and characterizing SMCs have been well described in 
1979 (Chamley-Campbell et al., 1979). Outgrowth of explants and enzyme dissociation are 
the two commonly used methods for obtaining SMCs from various blood vessels. Once 
SMCs are in subculture or have migrated from explants, they are not in contractile state but 
have phenotypically modulated and readily proliferate when stimulated with mitogens. The 
same phenotypic switch can be observed in vivo by electron microscopy following vascular 
injury. A large numbers of studies have revealed extensive alterations in gene expression and 
protein levels during phenotypic modulation and many factors have been shown to regulate 
this event. For example, smooth muscle α-actin is present in both synthetic (phenotypically 
changed) and contractile SMCs, whereas myosin heavy chain and smoothelin appear in the 
contractile state but not in the synthetic state (reviewed in Yoshida and Owens, 2005, Rensen 
et al., 2007). 
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For paper II, we used an enzyme dissociation method to isolate mouse pulmonary artery 
SMC for studies of cell proliferation and adhesion in vitro. This method yields a more 
heterogeneous, and perhaps more representative SMC population from the blood vessels. In 
contrast, explant methods will select cells that migrate quickly from the tissue. The main 
pulmonary arterial trunk and the proximal parts of the right and left pulmonary arteries were 
isolated under a stereomicroscope and the adventitia was gently removed. The blood vessels 
were then cut into small pieces and incubated with enzyme dissociation buffer (Ham's F-12 
Nutrient Mixture Glutamax medium with 0.5 mg/mL elastase, 2 mg/mL collagenase II, 0.375 
mg/mL soybean trypsin inhibitor, and 2 mg/mL BSA) for 2 h at 37 ºC. The cell suspension 
was then centrifuged, washed in F-12/0.1% BSA, and resuspended in the growth medium 
(Ham's F-12 Nutrient Mixture Glutamax medium with 20% fetal bovine serum, 50 µg/mL L-
ascorbic acid, 50 µg/mL streptomycin, and 50 IU/mL penicillin).  
Usually, 6 mice were needed for one cell isolation and pulmonary arteries were pooled. For 
the initiation of a culture 12-well plates were coated with bovine fibronectin (2.5 μg/cm2) and 
the cells were allowed to settle and adhere for 48 h before the first medium change. Growth 
medium was then changed every second day. In general, it takes 2 weeks to start a subculture. 
After passage 3, the cells can grow nicely in tissue culture flasks without fibronectin coating. 
Immunocytochemistry showed that >99% of the cells are positive for smooth muscle α-actin. 
CYCLIC CELL STRETCH 
In order to study the effect of mechanical strain on ECM protein production, we used a cyclic 
stretch apparatus kindly provided by Prof Staffan Johansson at Uppsala University. 
In preparation for the cell stretch experiments, silicon chambers (4x4 cm2 inner dimensions) 
were sterilized and the membranes were coated with bovine fibronectin (10 µg/cm2) during 
gentle shaking (Figure 18). Human pulmonary artery SMCs were then plated on the coated 
chambers and grown to subconfluence.  After changing the growth medium to DMEM 
containing 0.4% fetal bovine serum, 10% of biaxial cyclic stretch was applied to the silicone 
chambers with a frequency of 0.5 cycles per second. 
Following 6 h of cyclic stretch, a portion of cells were stained with trypan blue to assess cell 
viability. The medium was collected, and the cell layer was lysed for qPCR and Western blot. 
For metabolic labeling experiments, 50 µCi/mL of [35S]sulfate was added during 6 h of cyclic 
stretch and the samples were collected for proteoglycan and GAGs analysis.  
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Figure 18. Chambers for cyclic cell stretch 
For each stretch experiment new silicone membranes were attached to the bottom of the 
chambers. This procedure helps to acquire reproducible results. We tried to increase the 
frequency or the duration of the cyclic stretch. However, the cells detach very easily, which 
makes it difficult to mimic the in vivo conditions.  
ADDITIONAL METHODS 
Other methods used for this thesis like qPCR, Western blot, immunohistochemistry, cell 
proliferation assay, cell adhesion assay,  proximity ligation assay etc. follow standard 
protocols and were described in papers I-IV.   
 
 
 
 
 
 
 
10% Stretch 
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RESULTS AND DISCUSSION 
 
The overall aim of this thesis was to explore factors that can regulate SMC growth during PH 
development. In paper I and paper IV, we focused on PDGF-B and its role in pulmonary 
vascular remodeling. In paper II and paper III, we focused on two proteoglycans, perlecan 
and versican. We hypothesized that perlecan and versican in the ECM take part in the 
vascular remodeling process of PH, either directly or indirectly by regulating the 
bioavailability of growth factors. 
 
PAPER I. ANTENATAL IMATINIB TREATMENT REDUCES 
PULMONARY VASCULAR REMODELING IN A RAT MODEL OF 
CDH 
CDH is a birth defect associated with pulmonary hypoplasia and persistent pulmonary 
hypertension. Newborns with CDH display severe respiratory distress at birth. Despite 
oxygen therapy and optimal mechanical ventilation, some severe cases do not respond to 
inhaled nitric oxide and need ECMO. The intractable PH makes the medical care for these 
patients highly challenging. 
The abnormal pathological findings in CDH include poor development of the pulmonary 
vasculature and reduced alveologenesis. Increased vascular wall thickening and vascular 
hypercontractility are the hallmarks of PH in newborns with CDH. The vascular remodeling 
persists after surgical correction of diaphragm defect.  
Based on the report that the tyrosine kinase receptor inhibitor/PDGF receptor antagonist 
imatinib can reverse PH in animal models (Schermuly et al., 2005), we hypothesized that 
imatinib would reduce pulmonary remodeling in CDH by PDGF inhibition. Since PH is a 
problem already at birth in newborns with CDH, we aimed to evaluate the effect of antenatal 
imatinib treatment.  
In the rat model of nitrofen-induced PH, we showed that oral administration of imatinib to the 
rat dams resulted in reduced vascular remodeling in the pups. In the imatinib-treated CDH 
group, the morphological changes in the fetal rat lungs comprised reduced medial wall 
thickness, decreased proportion of fully muscularized pulmonary arteries, and increased 
vascular lumen area compared to the CDH group.  
We next explored the possible mechanism by evaluating cell proliferation and apoptosis. In 
CDH, the percentage of Ki-67-positive vascular cells is increased compared to control 
animals. The imatinib treatment significantly reduced the amount of Ki-67-positive cells, 
indicating inhibition of cell proliferation. We subsequently examined the protein levels of 
PDGFs and receptors by Western blot using whole lung homogenates, and by quantification 
of immunohistochemistry.  Both PDGF-B and PDGFR-β were significantly upregulated in 
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the CDH group compared to controls. The imatinib-treated CDH group revealed a trend 
towards down-regulation of PDGF-B and PDGFR-β compared to the CDH group, and a 
significant down-regulation of PDGFR-α was observed.  
In summary, we demonstrated that PDGF-B and PDGFR-β were increased in nitrofen-
induced CDH. Imatinib acts as an effective anti-remodeling agent by inhibition of cell 
proliferation. However, we also observed that the control group with imatinib treatment in the 
absence of nitrofen developed medial wall thinning and increased proportion of distal 
muscularized vessels. Even though there was no fetal lethality in our experiments, the drug 
safety still needs to be considered for clinical treatment. Indeed, imatinib has not been 
approved for PH treatment following clinical trials because of side effects, and it would not 
be advisable to give it during pregnancy. Studies of more specific pharmacological agents 
targeting PDGF-B/PDGFR-β are needed.  
 
PAPER II. PERLECAN HS DEFICIENCY IMPAIRS PULMONARY 
VASCULAR DEVELOPMENT AND ATTENUATES PH 
Heparin, the highly sulfated HS, was found to bind FGFs more than 30 years ago (Shing et 
al., 1984). It has also been shown that HS can either promote or inhibit cell growth (Imamura 
and Mitsui, 1987). Since then, a large number of studies have revealed dual regulation of 
heparin-binding growth factors by HSPGs, and provided evidence that HSPGs play a crucial 
role in fine tuning physiological events (reviewed in Lin, 2004, Bishop et al., 2007, Sarrazin 
et al., 2011). However, the role of HSPGs in pulmonary vascular remodeling had not been 
explored.  
As mentioned in the introduction, up-regulation of FGF-2 and PDGF-B has been shown in 
patients with PH and in animal models. Either FGF-2 or PDGF-B inhibition has been 
demonstrated to reverse experimental PH (Izikki et al., 2009, Schermuly et al., 2005). Since 
FGF-2 and PDGF-B can interact with HS by electrostatic mechanisms, we aimed to 
investigate the role of perlecan HS deficiency in PH development using the murine model of 
hypoxia-induced PH and examined the regulation of these growth factors by perlecan HS.   
The initiation of the study was based on previous work from our group where we showed 
increased intimal hyperplasia in Hspg2Δ3/Δ3 mice in a carotid ligation model and increased cell 
proliferation in Hspg2Δ3/Δ3 SMCs in vitro (Tran et al., 2004). In that study FGF-2 binding to 
ECM produced from Hspg2Δ3/Δ3 SMCs was significantly reduced compared to wild-type 
control. The increased intimal hyperplasia in Hspg2Δ3/Δ3 mice is likely due to defective 
sequestration of FGF-2 in the ECM, as a consequence of perlecan HS deficiency.  
Therefore, our initial prediction was that Hspg2Δ3/Δ3 mice would develop more severe 
hypoxia-induced PH. However, the results from our pilot experiments did not support this 
prediction. In addition, Hspg2Δ3/Δ3 mice constitutively revealed significantly less 
muscularization of pulmonary vessels with a diameter of 20-40 µm at baseline under 
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normoxic condition. To rule out that this phenotype was due to a defect in SMC 
differentiation, Western blot for several SMC markers was performed and no difference was 
seen in protein levels of SM-22, myosin heavy chain-11, and smooth muscle α-actin using 
aortic lysates.  
We then hypothesized that the reduction in muscularization was due to loss of mural cells. 
Staining for several pericyte markers like PDGFR-β, desmin, NG2, SMC α-actin was 
considerably more sparse  in the pulmonary vessels of Hspg2Δ3/Δ3 mice compared to wild-
type controls (vessel diameters  < 50 µm), as examined by confocal microscopy. This 
suggests loss of pericyte coverage in these vessels.   
Notably, the abovementioned vascular muscularization defect only appeared in the distal 
pulmonary arteries. Histologic examination of the pulmonary trunk and right and left 
pulmonary arteries was comparable with wild-type. The distal vascular muscularization 
defect possibly appeared in the embryo during the distal branching process in the pulmonary 
vascular development (Jones and Capen, 2011). We subsequently checked whether there was 
any defect in pulmonary vascular branching. Considering the availability of imaging 
modalities, we then chose X-ray angiography to rule out any arborization defect. In vivo X-
ray angiography revealed a peripheral filling defect in Hspg2Δ3/Δ3 lungs. However, the RVSP 
in normoxic Hspg2Δ3/Δ3 mice was normal.   
Based on the abnormal baseline in Hspg2Δ3/Δ3 mice, we next planned to investigate hypoxia-
induced pulmonary vascular remodeling at different time points (e.g. 3.5 days and 4 weeks). 
After 3.5 days of hypoxia exposure, both wild-type and Hspg2Δ3/Δ3 mice showed increased 
perlecan production. Importantly, cell proliferation was significantly reduced in Hspg2Δ3/Δ3 
pulmonary vessels. Following 4 weeks of hypoxia, Hspg2Δ3/Δ3 mice developed PH, but 
significantly less than wild-type mice. Reduced vascular remodeling and less right ventricular 
hypertrophy were observed in Hspg2Δ3/Δ3 mice.  
In order to dissect the molecular mechanisms, we checked the transcripts and protein levels of 
PDGF-B and FGF-2 and cognate receptors.  There were no differences between the 
genotypes in PDGF-B and PDGFR-β levels, but the hypoxia-induced increase in FGFR1 was 
inhibited in Hspg2Δ3/Δ3 mice following 3.5 days of hypoxia. In addition, we found FGF-2 
mRNA and protein levels to be significantly decreased in Hspg2Δ3/Δ3 mice compared to wild-
type following 4 weeks of hypoxia.  
Several studies have reported that perlecan either inhibits or promotes FGF-2 signaling 
(Aviezer et al., 1994, Pellegrini, 2001, Knox et al., 2002, Katta et al., 2013, Lord et al., 2014). 
To explore our results further we utilized the FGF ligand and carbohydrate engagement assay 
(Friedl et al., 2001) to examine the HS-FGF-2-FGFR1 complex formation both on lung 
sections and in vitro. The concept of this assay is that if HS-FGF-2 can form ternary 
complexes together with FGFR1, the HS in this condition is most likely to promote FGF-2 
signaling. On the other hand, when HS-FGF-2 binding cannot form a ternary complex with 
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FGFR1, HS possibly serves as a sequestration factor for FGF-2 storage. In wild-type mice, 
we detected fluorescence signals for HS-FGF-2-FGFR1 complexes. However, the signals for 
perlecan HS deficient mice were significantly reduced. This data suggested that perlecan HS 
takes part in HS-FGF-2-FGFR1 complex formation. This finding supports our Western blot 
analysis which showed that hypoxia-induced FGFR1 activation and protein levels were 
reduced in Hspg2Δ3/Δ3 lungs. We speculate that perlecan HS may function as a co-receptor or 
inhibit proteolysis by ternary complex formation (Figure 19). 
(A)                                                                               (B) 
      
Figure 19. (A)Possible mechanism of HS-FGF2-FGFR1 interaction.  (B)A similar 
mechanism has been proposed in HS-deficient CHO cells (a inducer-fit model in Yayon et al., 
1991). Reprinted with permission.   
In addition to reduced cell proliferation in hypoxic Hspg2Δ3/Δ3 lungs, proliferation of 
pulmonary artery SMCs from Hspg2Δ3/Δ3 mice was significantly reduced compared to wild-
type control cells under 1 % O2 with serum stimulation. However, no differences in growth 
were observed with PDGF-B or FGF-2 stimulation. It should be considered that the 
recombinant growth factors we used in the cell proliferation assay are not full-length 
polypeptides containing all HS-binding sites. Despite that they induced biological activities; 
the recombinant polypeptides may not exert the full function. The electrostatic interactions 
between growth factors and perlecan HS are possibly not present completely. 
To ensure HS deficiency in isolated SMCs from Hspg2Δ3/Δ3 mice, we also checked the level 
of perlecan core protein and HS in the SMC cultures. The results were consistent with our 
previous finding, which showed reduced HS levels in SMCs from Hspg2Δ3/Δ3 mice compared 
to those from wild-type mice (Figure 20).  
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Figure 20. Results from cell-based ELISA showed that Hspg23/3 SMCs produced 
significantly less HS compared to wild-type control cells. No difference in perlecan core 
protein content was seen. SMCs from wild-type and perlecan mutant mice were plated in 96 
well plates with increasing seeding density (500-5000 cells/cm2) in quadruplicates for 3 days. 
The cells and pericellular matrix were then fixed with 4% zinc-formaldehyde and blocked 
with 5% BSA, followed by double-staining with a mouse monoclonal anti-heparan sulfate 
antibody (clone 10E4) and a rabbit polyclonal anti-perlecan antibody (R14). After 
incubation with secondary antibodies conjugated with IRDye 680 and IRDye 800 CW, and 
washing steps, the plates were read using an Odyssey CLx infrared imaging system (LI-
COR). The data are presented as mean ±SEM.  
 
In conclusion, this study highlights the importance of perlecan HS in pulmonary vascular 
development as well as in the vascular remodeling of PH. Perlecan HS deficiency results in 
impaired mural cell recruitment to pulmonary vessels and reduced hypoxia-induced PH, 
partially explained by impaired FGF-2-FGFR1 interaction and inhibition of SMC growth. 
Future studies on the glycan structure of perlecan HS may help to elucidate the diversity of 
perlecan HS function.  
 
PAPER III. VERSICAN ACCUMULATES IN VASCULAR LESIONS IN 
PAH. 
Versican is the major CSP in the vascular wall (Theocharis et al., 2001). In systemic blood 
vessels, versican is upregulated in restenosis and atherosclerosis, where increased versican is 
associated with SMC proliferation, inflammation and lipid retention (Wight, 2002, Wight and 
Merrilees, 2004). By metabolic labeling of aortic SMCs, PDGF has been shown to upregulate 
versican core protein synthesis, change GAG composition, and stimulate elongation of GAGs 
through protein kinase C and extracellular signal-related kinase (ERK) pathways (Schonherr 
et al., 1991, Cardoso et al., 2010). However, the role of versican in PH is unknown.  
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In paper III, we hypothesized that versican would be upregulated in vascular lesions in PH. 
We used lung tissue samples from patients with PAH of different etiologies, and studied 
versican levels in various types of vascular lesions. By immunohistochemistry and Western 
blot, we confirmed that versican is increased in lungs of PAH patients compared to those of 
healthy donors. Versican prominently accumulates in the vascular ECM in PAH, including in 
neointima, in medial hypertrophy and plexiform lesions. Accumulation of versican was seen 
in lungs from patients with idiopathic PAH, PAH associated with scleroderma, and PAH as a 
result of congenital heart disease. 
Notably, versican deposition does not correlate with leukocyte infiltration in the tissue 
sections we used, as examined by double staining for versican and CD45. However, we 
cannot exclude a possible role for versican in inflammation in PAH. Vascular remodeling is a 
dynamic process and the methodology we used here does not allow analysis of different time 
points during disease progression.  The only time point available was the time of transplant, a 
time when the PH of course is in a very advanced stage. 
We then set up in vitro studies to explore the factors that can regulate versican production by 
PASMCs. We first checked the regulation of versican production by different growth factors 
like PDGF-B and FGF-2, but no differences were found using Western blot.  
Based on the finding that versican accumulation was not dependent on the underlying 
etiology of PAH, we hypothesized that increased mechanical strain and hypoxia could be 
important factors to promote versican production, considering the pathophysiological 
environment in pulmonary circulation in PAH. We used metabolic labeling with [35S]sulfate 
to study proteoglycan synthesis during exposure to mechanical strain/cyclic stretch.  
Analyses of [35S]sulfate-labeled proteoglycans synthesized by PASMCs showed that the 
majority of GAGs in medium samples are CS/DS, whereas GAGs in cell layer samples are 
HS and CS/DS. During 6 h of 10% biaxial cyclic stretch with a frequency of 0.5 Hz, the 
hydrodynamic size of proteoglycans was not changed compared to the non-stretch control 
samples. However, we observed that the peak representing small proteoglycans, possibly 
biglycan or decorin, disappeared following 6 hr of stretch. 
Similar to the metabolic labeling, qPCR and Western blot analysis of PASMCs from stretch 
experiments did not reveal any increase in versican levels during 6 h of cyclic stretch, while 
the positive control consisting of aortic SMCs from the same healthy donor showed increased 
versican gene expression and protein accumulation after 6 h of stretch, consistent with a 
report in 2001 (Lee et al., 2001).  However, increased versican mRNA and protein levels 
were observed in PASMCs when the samples were collected at 12 h. Versican synthesis by 
PASMCs thus appeared to be less responsive to mechanical stretch compared to aortic cells 
and the PASMCs also seemed to produce a lower amount of versican at baseline, which in 
part may explain why immunostaining and Western blot showed very little versican 
deposition in the healthy donor lungs.  
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As mentioned in the “Introduction” section, HIF-1α is an essential element in hypoxia-
induced pulmonary vascular remodeling in PH (Ball et al., 2014). It has also been reported 
that HIF-1α is associated with a high level of proangiogenic progenitor cells in the circulation 
of patients with PAH (Farha et al., 2011). Recently, a study by Asplund et al. reported that 
the versican gene, VCAN, has an hypoxia response element, DNA sequence 5'-[AG]CGTG-
3', in the promoter region, and that versican gene expression in macrophages is regulated by 
HIF-1α and HIF-2α (Asplund et al., 2010) . Here we observed increased versican gene 
expression and protein synthesis in PASMCs following 24h of incubation at 1% O2, as 
evaluated by qPCR and Western blot.  The association between HIF-1α and versican in PAH 
awaits further investigation.  
In our Western blots, using cell lysates or tissue homogenates, several versican fragments 
were detected. However, we were unable to differentiate different versican isoforms from 
versican degradation products. Since Western blot for versican requires DEAE-Sephacel 
purification, dialysis, and deglycosylation it is difficult to avoid partial degradation, despite 
the use of protease inhibitors.  
In addition, for the lung homogenates, various types of proteases exist in the tissue and the 
degradation process in vivo may be increased in the pathological state. The altered 
proteoglycan turnover makes it difficult for us to interpret the Western results. Furthermore, 
SDS-PAGE separates the protein by molecular weight and the antibodies for immunoblotting 
recognize specific peptide sequences which may be present in some intact isoforms as well as 
in degradation fragments.  
Our finding of versican accumulation in PAH may be associated with aberrant elastin 
turnover. CS, the part of versican, has been shown to cause shedding of elastin binding 
protein from the surface of SMCs, and to thereby impair elastic fiber assembly (Hinek et al., 
1991). On the other hand, overexpression of V3, the isoform without CS, is able to create an 
elastin-rich ECM in blood vessels (Merrilees et al., 2002, Merrilees et al., 2011). We 
speculate that versican accumulation in PH, in combination with increased elastin 
degradation, results in a water-rich vascular ECM.  The environment in the ECM thereby 
shifts from a hydrophobic state to a hydrophilic state, which facilitates cell migration and 
proliferation. 
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PAPER IV. LACK OF PDGF-B RETENTION AMELIORATES 
HYPOXIA-INDUCED PULMONARY HYPERTENSION 
 
In paper IV, we aimed to evaluate the effect of lack of PDGF-B retention motifs on 
pulmonary vascular remodeling in the murine model of hypoxia-induced PH. Pdgfbret/ret mice 
expressing PDGF-B lacking the C-terminal retention motifs were used for the study. 
Pdgfbret/ret mice are difficult to breed and heterozygous breeding generates too few 
homozygous knockout animals.  Homozygote with heterozygote breeding was therefore used 
for generating knockouts and Pdgfbret/+ heterozygous littermates, which were used as 
controls. This generated four groups, Pdgfbret/ret normoxia, Pdgfbret/+ normoxia, Pdgfbret/ret 
hypoxia, and Pdgfbret/+ hypoxia. Normoxic groups were kept in room air and hypoxic groups 
were exposed to 10% O2 for 4 weeks.  
Pdgfbret/ret mice have impaired pericyte investment in the microvessels of the brain, 
albuminuria and retinopathy (Lindblom et al., 2003). In addition, increased collagen content, 
endothelial dysfunction and vascular stiffness have been observed in the aorta of Pdgfbret/ret 
mice whereas the number of vascular SMCs and systemic arterial pressure are normal. 
Adaptive eccentric cardiac hypertrophy is present in Pdgfbret/ret mice, possibly due to a 
hyperkinetic circulation (Nystrom et al., 2006). 
We examined the gross histology of Pdgfbret/ret lungs by H&E staining and Masson’s 
trichrome staining, and no obvious structural abnormalities or signs of fibrosis were found. 
The RVSP in Pdgfbret/ret mice was also comparable with that in Pdgfbret/+ control mice at 
baseline (in normoxia). 
After 4 weeks of hypoxia, both genotypes developed PH, but the RVSP in Pdgfbret/ret mice 
was significantly lower. In addition, right ventricular hypertrophy was absent in Pdgfbret/ret 
mice following chronic hypoxia. In summary, the data suggested that lack of PDGF-B 
retention reduces hypoxia-induced PH.  
We then examined the pulmonary vascular remodeling by immunofluorescence and 
morphometric analysis. Following 4 weeks of hypoxia, an increase in fully muscularized 
intra-acinar vessels was seen in Pdgfbret/+ mice. Pdgfbret/ret mice however developed a greater 
proportion of partially muscularized vessels, and no significant increase in fully muscularized 
vessels. Notably, in the Pdgfbret/ret mice smooth muscle-α-actin-positive cells were present in 
the alveolar interstitial space in a scattered distribution (Figure 6F in paper IV). This 
disorganized muscularization pattern may suggest that PDGF-B is not confined to the 
vascular ECM. Instead, PDGF-B may diffuse freely along the alveolar septae (Figure21).  
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           (A) Pdgf-bret/+ mice                                            (B)Pdgf-bret/ret mice 
                               
 
Figure 21. Working hypothesis for PDGF-B retention in vascular ECM. (A)PDGF-B is 
confined in the vascular ECM by interacting with HSPGs like perlecan and syndecan. 
(B)Knockout of PDGF-B retention results in PDGF-B diffusion and SMC disarrangement.   
 
Since PDGF-B is essential for the recruitment of pericytes and SMCs (Lindahl et al., 1997, 
Hellstrom et al., 1999), we hypothesize that loss of PDGF-B retention results in defective 
restraint of mural cell migration. Defective PDGF-B gradients and reduced ability to form 
fully muscularized vessels following hypoxia may be the reason why Pdgfbret/ret mice seems 
to be protected from developing PH. To test this hypothesis, more experiments are needed for 
this project. The first will be to elucidate the identity and morphology of the smooth muscle-
α-actin-positive cells in the alveolar septae by high-resolution confocal microscopy and 
immunofluorescence staining for different pericyte markers and SMC differentiation markers. 
In addition, it would be very interesting if we can visualize a different tissue distribution of 
PDGF-B in the Pdgfbret/ret lungs. To count vessels per 100 alveoli in normoxia and hypoxia 
will also be important since angiogenesis and vascular stability may be affected in the 
animals. PDGF-B and PDGFR transcripts and protein levels in whole lung lysates also need 
to be quantified since ECs from Pdgfbret/ret mice have been shown to synthesize reduced 
levels of PDGF-B in vitro. If possible, it would also be of interest to set up an in vitro 
migration co-culture assay for studies of mural cell recruitment.    
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CONCLUDING REMARKS 
 
In conclusion, the studies in this thesis demonstrate that growth factors and proteoglycans are 
important regulators of SMC growth during vascular remodeling in PH. 
Growth factors, like PDGF-B and FGF-2, promote SMC proliferation and migration and thus 
drive the vascular repair process in PH. In addition to growth factors, proteoglycans in the 
ECM participate in PH development. Perlecan is upregulated in the mouse model of hypoxia-
induced PH, where perlecan HS regulates FGF-FGF receptor interactions by supporting 
ternary complex formation. Versican accumulates in the vascular ECM in patients with PAH, 
which is associated with hypoxia and increased mechanical strain. The overproduction of 
these proteoglycans may in turn regulate cell phenotype in PH progression, either directly or 
indirectly by controlling the bioavailability of growth factors and cytokines. 
This thesis work reveals several possible targets for anti-remodeling treatment of PH. In 
addition to PDGF receptor inhibition, the PDGF retention motif, perlecan HS, and versican 
may provide potential anti-proliferative targets for PH therapy.  
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FUTURE PERSPECTIVES 
 
As we have demonstrated in paper II, perlecan HS deficiency inhibits PASMC growth and 
reduces hypoxia-induced PH. We speculate that perlecan HS either serves as a co-receptor or 
provides a steric hindrance that can protect FGF-2 from proteolytic degradation. However, in 
the carotid artery, the results are opposite. Previous studies have also reported dual effects of 
perlecan HS (Knox et al., 2002, Lord et al., 2014), but the exact mechanism which accounts 
for this dual regulation has not been explored. It is possible that the glycan structure of 
perlecan HS is cell type-specific and different environmental stimuli may also affect the post-
translational modifications. Despite the difficulty to predict the 3-dimensional structure of HS 
together with the core protein, the modulation of growth factor activity by HS seems to be 
very specific and effective. It would therefore be of value to analyze the glycan structure of 
perlecan HS from different cell-types and different tissues, and further dissect the molecular 
mechanisms in order to design new pharmacological agents.   
 
In paper III we have identified versican accumulation in patients with PAH. Hypoxia and 
increased mechanical strain may explain the excessive versican deposition in the vascular 
ECM in PH. More mechanistic studies are needed to understand the regulation by hypoxia 
and mechanical strain. Further studies on versican function may provide valuable insights 
into the vascular remodeling process. In addition, the studies of systemic arteries have 
reported that overexpression of the V3 variant of versican in blood vessels results in a 
multilayered and elastin-enriched neointima (Merrilees et al., 2011).  It will be of interest to 
test V3 delivery in an animal model of PH and examine the effect on the vascular remodeling 
process. 
 
In general, studies of pulmonary vascular remodeling in animal model of PH would benefit 
greatly from better non-invasive imaging modalities for hemodynamic measurements at serial 
time points. Changes of blood flow in the pulmonary circulation and in the right heart 
chamber are of importance for the tissue remodeling process. However, this information is 
largely unknown for the commonly used animal models. High throughput histologic analysis 
for systematic evaluation of vascular remodeling in the pulmonary vascular tree is also 
needed for obtaining more precise data, which is especially important for the detection of 
subtle changes in genetically modified mice.  
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